Johnson & Johnson (JNJ)

JNJ on New York Consolidated

101.35USD
22 May 2015
Change (% chg)

$-1.07 (-1.04%)
Prev Close
$102.42
Open
$102.27
Day's High
$102.41
Day's Low
$101.33
Volume
6,216,965
Avg. Vol
7,859,967
52-wk High
$109.49
52-wk Low
$95.10

JNJ

Chart for JNJ

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.52
Market Cap(Mil.): $281,048.19
Shares Outstanding(Mil.): 2,773.04
Dividend: 0.75
Yield (%): 2.96

Financials

  JNJ Industry Sector
P/E (TTM): 18.14 37.22 39.17
EPS (TTM): 5.59 -- --
ROI: 14.86 16.24 15.58
ROE: 22.04 16.99 16.57
Search Stocks

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

UPDATE 2-J&J to submit at least 10 new drugs for approval by 2019

May 20 - U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

CORRECTED-UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19)

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

20 May 2015

Achillion partners with J&J to develop hepatitis C drugs

- Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

19 May 2015

UPDATE 1-Achillion partners with J&J to develop hep C drugs

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

19 May 2015

Achillion partners with J&J to develop hep C drugs

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market one or more of its hepatitis C drugs.

19 May 2015

FDA approves longer-acting version of J&J's schizophrenia drug

May 19 - The U.S. Food and Drug Administration approved a longer-acting version of Johnson & Johnson's schizophrenia treatment, developed by the company's Janssen Pharmaceuticals unit.

19 May 2015

FDA warns on newer class of type 2 diabetes drugs

- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

15 May 2015

UPDATE 2-U.S. FDA warns on newer class of type 2 diabetes drugs

May 15 - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

15 May 2015

Earnings vs. Estimates

Search Stocks